Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

https://www.fosunpharma.com/en/

Latest From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Next Potential Big ADC Player? Korean Firms Take It Up A Notch

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

South Korea Research & Development

Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist

Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.

Deal Watch Business Strategies

Lockdown To Reopening: China Rebound Uncertain As Biotech Remains In Survival Mode

The short-notice reopening of the country made 2022 a tough year for the health sector in China, where divestments, cash crunches and commercial challenges abounded. Throughout the year, despite clinical trial activity continuing to blossom, multiple Chinese innovative drug developers faced setbacks in the US from regulatory rejections of oncology products. Meanwhile, others quietly scaled back their operations in China, hit by the negative impact of deep price cuts.

China Scrip Perspectives

10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot

From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.

China Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Ahon Pharmaceutical Co., Ltd.
    • Fosun Kite Biotechnology Co., Ltd.
    • Fosun Pharma Kite Biotechnology Co. Ltd.
    • Guilin Pharma
    • Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.
    • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Shenyang Hongqi Pharmaceuticals Co., Ltd.,
    • Fosun Industrial Co., Limited
UsernamePublicRestriction

Register